Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment

Current Rheumatology Reports
Cecilia Beatrice Chighizola, Pier Luigi Meroni

Abstract

The aim of this review is to provide an update of the therapeutic tools for thrombotic anti-phospholipid syndrome (APS), focusing on the last 5 years. Early studies appointed anticoagulation at moderate intensity as the mainstay of treatment of thrombotic APS; in the last 5 years, the strategy has not much mutated. Some uncertainties regarding the role of direct oral anticoagulants and the optimal regimen for arterial thrombotic APS still persist: high-intensity anticoagulation, anticoagulation plus anti-platelet agent, and double anti-platelet agents being the possible alternatives. Several drugs have been proposed as effective additional tools for the management of thrombotic APS: hydroxychloroquine, statins, vitamin D, and sirolimus might be beneficial when added on the top of anticoagulation. Pregnant women with thrombotic APS should be switched to low-dose aspirin plus low molecular weight heparin at therapeutic dose. Despite adequate treatment, APS patients display a significant rate of recurrences; rituximab, eculizumab, and intravenous immunoglobulins are among the options to be considered for these patients. From 2013 to date, the kaleidoscope of therapeutic options in thrombotic APS has been enriched, but tangible imp...Continue Reading

References

Apr 16, 2002·Arthritis and Rheumatism·Ricard CerveraUNKNOWN Euro-Phospholipid Project Group
Dec 1, 2007·Arthritis and Rheumatism·Guillermo Ruiz-IrastorzaMunther A Khamashta
Sep 20, 2008·Annals of the Rheumatic Diseases·R CerveraUNKNOWN Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies)
Jan 22, 2014·Systematic Reviews·Claire M LawleyChristine L Roberts
Jun 20, 2014·Annals of the Rheumatic Diseases·Savino SciasciaUNKNOWN APS Action
Jul 24, 2014·The New England Journal of Medicine·Guillaume CanaudFabiola Terzi
Dec 3, 2014·Revista brasileira de reumatologia·Felipe Freire da Silva, Jozélio Freire de Carvalho
Jun 16, 2015·Journal of Immunology Research·Cecilia Beatrice ChighizolaPier Luigi Meroni
Jan 19, 2016·Journal of Thrombosis and Thrombolysis·Allison E BurnettJack Ansell
Jul 29, 2016·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Mauricio Mora-RamírezLuis M Amezcua-Guerra
Mar 10, 2017·Seminars in Thrombosis and Hemostasis·Cecilia Beatrice ChighizolaPier Luigi Meroni
Jun 3, 2017·The Journal of Rheumatology·Mara TaraborelliAngela Tincani
Sep 1, 2017·Expert Opinion on Drug Safety·Marta Pérez-De-LisManuel Ramos-Casals
Sep 13, 2017·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Scott C WollerMatthew T Rondina
Nov 12, 2017·Seminars in Arthritis and Rheumatism·Leyre Riancho-ZarrabeitiaVíctor M Martínez-Taboada
Feb 17, 2018·Journal of Autoimmunity·Cecilia Beatrice ChighizolaPier Luigi Meroni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Related Papers

Journal of Autoimmunity
Cecilia Beatrice ChighizolaPier Luigi Meroni
Expert Opinion on Pharmacotherapy
Gerard Espinosa, Ricard Cervera
Current Rheumatology Reports
Kessarin PanichpisalSteven R Levine
© 2022 Meta ULC. All rights reserved